• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors

    4/22/22 6:34:00 AM ET
    $CDXC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDXC alert in real time by email

    ChromaDex Corp. (NASDAQ:CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vice President and Chief Financial Officer of The Institute of Internal Auditors (The IIA).

    "We welcome Ms. Patrick and Ms. Cohen to our distinguished ChromaDex Board of Directors," said Rob Fried, CEO of ChromaDex. "Ms. Patrick has overseen some of the world's most recognizable and respected consumer brands, and Ms. Cohen is an executive with significant financial expertise and of strong personal integrity. We are excited and honored to be working with them both."

    As the Executive Vice President and Chief Marketing Officer at Claire's Inc., Ms. Patrick is part of the executive team leading the transformation of the youth culture brand. Prior to joining Claire's Inc., Ms. Patrick was the Senior Vice President and Chief Marketing Officer of Brand Strategy & Development at PepsiCo where she was responsible for long-term brand vision across the PepsiCo portfolio. Additionally, as the Chief Marketing Officer at Playboy Enterprises, Ms. Patrick was responsible for ushering the brand into a new era and rebuilding relevancy including developing the brand architecture, positioning, and implementing a new business strategy across all businesses.

    Ms. Patrick's 20+ year career spans multiple industries such as fashion, omnichannel retail, entertainment, Consumer Packaged Goods, beauty and includes expertise across food, drug, convenience mass, luxury, mid-tier and Direct to Consumer channels. In addition to Claire's Inc., PepsiCo and Playboy Enterprises, she has held positions at Disney, Calvin Klein, Gap, Inc., Revlon, and Liz Claiborne. Ms. Patrick has developed a distinguished reputation for being a disruptive, trend-setting brand steward, general manager, and strategist.

    At The IIA, Ms. Cohen​​ oversees all financial, risk management, and information technology and is ​​both a Certified Public Accountant (Florida) and a Certified Global Management Accountant. Prior to joining The IIA, Ms. Cohen served in senior financial leadership roles for both public and private companies including Taylor Morrison Homes (formerly Taylor Woodrow), a $2.5 billion international residential home builder, and Starwood Vacation Ownership, a $600 million international division of Starwood Hotels and Resorts.

    In her career, Ms. Cohen has overseen financial reporting under Generally Accepted Accounting Principles (GAAP) and International Financial Reporting Standards (IFRS), business planning and analysis, financial and operational strategies, human resources, information technology, enterprise risk management, the acquisition and disposition of projects, and regulatory reporting including SEC reporting. Ms. Cohen has also worked closely with various public accounting firms and audit committees.

    Jeff Baxter and Caroline Levy resigned from the Board, and Kurt Gustafson and Steve Block will not seek re-election to the Board at the Company's annual meeting for stockholders, expected to be held in June 2022. ChromaDex thanks them all for their valuable contributions.

    For additional information on ChromaDex, visit www.chromadex.com.

    About ChromaDex:

    ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex's patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

    Forward-Looking Statements:

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the Company's domestic and international growth strategies and expected timing of the annual meeting of stockholders. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005137/en/

    Get the next $CDXC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDXC

    DatePrice TargetRatingAnalyst
    8/16/2022Outperform → Perform
    Oppenheimer
    8/11/2022$6.00 → $2.40Buy → Neutral
    B. Riley Securities
    3/10/2022$16.00 → $8.00Buy
    B. Riley Securities
    3/8/2022$7.00Buy
    ROTH Capital
    8/4/2021$11.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CDXC
    SEC Filings

    See more
    • ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

      3/19/25 8:32:16 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ChromaDex Corp. (0001386570) (Filer)

      3/4/25 4:02:10 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-K filed by ChromaDex Corporation

      10-K - ChromaDex Corp. (0001386570) (Filer)

      3/4/25 4:01:06 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDXC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

      ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol "NAGE" effective at stock market open on Wednesday, March 19, 2025. As part of this transition, the Company will deploy a follow-up announcement with additional updates regarding the name change, rebrand, and future initiatives. No action is required by existing shareholders with respect to the ticker symbol change. The Company's common stock will continue to be listed on Nasdaq and the CUSIP will remain unchanged. For additional

      3/13/25 8:34:00 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex to Present at the 37th Annual Roth Conference

      ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference. ChromaDex CEO, Rob Fried, will participate on the Longevity and Supplementation Panel on Monday, March 17, at 12:00 PM PT (3:00 PM ET). Panels will be livestreamed and available at https://wsw.com/webcast/roth50. Additionally, ChromaDex's CEO, Rob Fried, and CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutional investors throughout the day. This year's event will consist of one-on-one and small group meetings, analyst-selected fireside

      3/11/25 4:04:00 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

      Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million. ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0%

      3/4/25 4:02:00 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)

      4 - ChromaDex Corp. (0001386570) (Issuer)

      3/10/25 8:11:11 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Fried Robert N

      4 - ChromaDex Corp. (0001386570) (Issuer)

      2/27/25 4:42:35 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by SVP, General Counsel Lopez Carlos Luis

      4 - ChromaDex Corp. (0001386570) (Issuer)

      2/14/25 6:19:33 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDXC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)

      4 - ChromaDex Corp. (0001386570) (Issuer)

      3/10/25 8:11:11 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Pamir Ozan bought $21,397 worth of shares (2,907 units at $7.36) (SEC Form 4)

      4 - ChromaDex Corp. (0001386570) (Issuer)

      11/25/24 7:28:56 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Gerber Brianna bought $7,050 worth of shares (5,000 units at $1.41), increasing direct ownership by 22% to 27,436 units (SEC Form 4)

      4 - ChromaDex Corp. (0001386570) (Issuer)

      12/4/23 4:12:33 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDXC
    Financials

    Live finance-specific insights

    See more
    • ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

      Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37% from the prior year, gross margin of 62.5%, and net income of $7.2 million. ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 million, with $22.7 million from Tru Niagen®, up 37% and 29%, respectively, from the prior year quarter. Posted strong gross margin of 62.5%, up 150 basis points from 61.0%

      3/4/25 4:02:00 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

      ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2024 financial results, which ended December 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, March 4, 2025. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the fourth quarter and fiscal year 2024 results and provide a general business update on Tuesday, March 4, 2

      2/25/25 4:07:00 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex Corporation Reports Third Quarter 2024 Financial Results

      Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024 ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY. Delivered strong gross margin of 63.5%, up 210 basis poi

      10/31/24 4:04:00 PM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDXC
    Leadership Updates

    Live Leadership Updates

    See more
    • ChromaDex Appoints Ozan Pamir as Chief Financial Officer

      ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets through investor relations. Effective October 21, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Mr. Fried commented, "We are very pleased to welcome Ozan to the ChromaDex team. His ambitious work ethic and impressive professional background will help us to embark on this critical next phase of develo

      9/20/24 8:32:00 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

      ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today, July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru Niagen®. Carlos Lopez is a distinguished legal professional and executive leader with expertise in the dietary supplements industry. Prior to joining ChromaDex, he served as the Vice President, General Counsel at The Vitamin Sh

      7/22/24 8:34:00 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex to Join Russell 2000® Index

      ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024. Rob Fried, CEO of ChromaDex and Founder of Tru Niagen commented, "Joining the Russel

      7/1/24 8:32:00 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDXC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ChromaDex downgraded by Oppenheimer

      Oppenheimer downgraded ChromaDex from Outperform to Perform

      8/16/22 7:48:02 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • ChromaDex downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded ChromaDex from Buy to Neutral and set a new price target of $2.40 from $6.00 previously

      8/11/22 7:50:39 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • B. Riley Securities reiterated coverage on ChromaDex with a new price target

      B. Riley Securities reiterated coverage of ChromaDex with a rating of Buy and set a new price target of $8.00 from $16.00 previously

      3/10/22 11:34:24 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDXC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

      SC 13D/A - ChromaDex Corp. (0001386570) (Subject)

      8/21/24 6:06:58 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ChromaDex Corporation

      SC 13D/A - ChromaDex Corp. (0001386570) (Subject)

      8/21/24 6:05:57 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by ChromaDex Corporation (Amendment)

      SC 13D/A - ChromaDex Corp. (0001386570) (Subject)

      9/7/23 6:20:26 AM ET
      $CDXC
      Medicinal Chemicals and Botanical Products
      Health Care